Casdin Capital’s Audentes Therapeutics, Inc BOLD Stock Holding History

Casdin Capital’s Portfolio BOLD Stock Details BOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-860,000	Closed	-$51.5M	–	40
2019 Q4	$51.5M	Hold	860,000	–	–	4.73%	9
2019 Q3	$24.2M	Sell	860,000 -105,000	-11%	-$3.58M	2.5%	14
2019 Q2	$36.5M	Sell	965,000 -45,000	-4%	-$1.73M	3.42%	13
2019 Q1	$39.4M	Buy	1,010,000 +150,000	+17%	+$4.3M	4.33%	12
2018 Q4	$18.3M	Buy	860,000 +235,000	+38%	+$6.06M	3.14%	14
2018 Q3	$24.7M	Buy	625,000 +175,000	+39%	+$6.52M	3.01%	16
2018 Q2	$17.2M	Hold	450,000	–	–	2.4%	18
2018 Q1	$13.5M	Buy	450,000 +50,000	+13%	+$1.69M	2.38%	19
2017 Q4	$12.5M	Hold	400,000	–	–	3.04%	16
2017 Q3	$11.2M	Hold	400,000	–	–	3.16%	16
2017 Q2	$7.65M	Buy	400,000 +140,000	+54%	+$2.24M	2.83%	15
2017 Q1	$4.43M	Buy	+260,000	New	+$4.21M	2.61%	11

Casdin Capital's BOLD Position: Q1 2020 in Review

Casdin Capital sold out of Audentes Therapeutics, Inc (BOLD) in Q1 2020, closing a stake of 860,000 shares — an estimated $51.5M sold.

Casdin Capital first reported a position in BOLD in Q1 2017 and held it in 12 quarters. The position peaked at $51.5M in Q4 2019. 0 funds tracked by Wall St. Rank hold BOLD as of Q1 2020.

Casdin Capital reported no remaining Audentes Therapeutics, Inc position as of Q1 2020 after selling out during the quarter.
Casdin Capital sold 860,000 Audentes Therapeutics, Inc shares in Q1 2020, an estimated $51.5M.
Casdin Capital first reported a position in Audentes Therapeutics, Inc in Q1 2017 and held it in 12 quarters.
Casdin Capital's Audentes Therapeutics, Inc position peaked at $51.5M in Q4 2019.
0 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q1 2020.

Based on Casdin Capital's 13F filing for Q1 2020, filed 15 May 2020.